MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Heterogeneity of multiple system atrophy with an analysis of the clinical case

    M. Karzhaubayeva (Almaty, Kazakhstan)

    Objective: Multiple system atrophy (MSA) is a rapidly progressive neurodegenerative disease clinically characterized by various combinations of Parkinsonism with resistance to levodopa, cerebellar, autonomic, and…
  • 2024 International Congress

    Is cathepsin D a good target for therapy in Tau-related conditions?

    G. Kovacs, A. Jafrani, G. Puska, I. Martinez-Valbuena, S. Lee, S. Knott, A. Karakani, S. Tanikawa, A. Lang, S. Forrest (Toronto, Canada)

    Objective: To study the involvement of cathepsin D in the pathogenesis of Tau-related conditions. Background: The endo-lysosomal system (ELS) is central in processing of neurodegenerative…
  • 2024 International Congress

    Brain De-Ironization with Nasal Spray of Iron Chelator in Treatment of Multiple System Atrophy, a Case Trial

    A. Amoushahi, A. Sahebkar, P. Moeini, N. Chitsaz (Isfahan, Islamic Republic of Iran)

    Objective: Iron removal seems to be a treatment approach in Multiple system atrophy (MSA) because pathological findings shows the accumulation of iron and α-synuclein protein…
  • 2024 International Congress

    Treatment Patterns and Comorbidities Associated with Multiple System Atrophy: A Comparative Study

    S. Kaplan, H. Xie, A. Kumar (Netanya, Israel)

    Objective: To examine comorbidities and co-medications in patients with multiple system atrophy (MSA) compared to a matched-control in real-world setting Background: Currently MSA is managed…
  • 2024 International Congress

    Clinical characteristics and Brain atrophy pattern in the prospective multicenter cohort of Progressive Supranuclear Palsy

    S. Lee, R. Kim, B. Jin, H. Kim, EJ. Yoon, YK. Kim, JH. Shin, HJ. Kim, JY. Lee (Seoul, Republic of Korea)

    Objective: This study aims to investigate volumetric brain MRI features, clinical parameters and their correlations in the Study of Comprehensive ANd multimodal marker-based Cohort of…
  • 2024 International Congress

    Safety and Efficacy of the Anti-alpha Synuclein Monoclonal Antibody Lu AF82422 for the Treatment of Patients with MSA: Results from the Phase 2 AMULET Trial

    W. Singer, S. Zanigni, L. Kjærsgaard, J. Wiedemann, P. Kallunki, K. Kompus, M. Jørgensen, M. Flensburg, A. Bidani, JL. Molinuevo, A. Takeda, B. Grønning, J. Luthman (Rochester, USA)

    Objective: Assess the efficacy and safety of monthly IV infusions with the anti-alpha synuclein [a-syn] monoclonal antibody Lu AF82422 for the treatment of patients with…
  • 2024 International Congress

    Prevalence of autonomic symptoms in Multiple System Atrophy on the background of probable RBD

    H. Karkourian, L. Atabekyan, N. Nadryan, E. Balian, A. Grigoryan, S. Khachatryan, Z. Tavadyan (Yerevan, Armenia)

    Objective: To discover whether having probable rapid eye movement sleep behavior disorder (RBD) affects prevalence of particular autonomic symptoms, namely falls, constipation and urinary incontinence…
  • 2024 International Congress

    Unsupervised Learning Approach for Pathology-Based Subtyping and Staging Multiple System Atrophy

    H. Sekiya, D. Ono, D. Dickson (Jacksonville, USA)

    Objective: To develop a classification and staging system for multiple system atrophy (MSA) using data-driven disease progression modeling. Background: MSA exhibits varying degrees of degeneration…
  • 2024 International Congress

    Lyme disease presenting as a rapidly progressive MSA-C look alike

    L. Zünd-Hofer, F. Brugger (Sankt Gallen, Switzerland)

    Objective: We report two cases of encephalomyelitis due to Lyme disease with cerebellar ataxia and autonomic symptoms, which presented with a rapidly progressive MSA-like phenotype.…
  • 2024 International Congress

    Inclusion of PSP-Parkinsonism (PSP-P) phenotype in clinical trials – power calculation

    N. Olfati, S. Akhlaghi, A. Shoeibi, I. Litvan (San Diego, USA)

    Objective: PSP-P is the second most common PSP phenotype. To facilitate its inclusion in future clinical trials, we used longitudinal data from the TAUROS study…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 1554
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley